Palavras-chave
Neoplasias de la próstata
Metástasis de la neoplasia
Adenocarcinoma
Carcinomatosis peritoneal
Como Citar
Resumo
La carcinomatosis peritoneal es una entidad poco común y de mal pronóstico, evidenciada en metástasis principalmente de origen gastrointestinal y ovárico. Sin embargo, es infrecuente que se desarrolle por adenocarcinoma prostático. Se presenta el caso de un adulto mayor con síndrome constitucional asociado a ascitis maligna, de dos meses de evolución. La tomografía reveló múltiples lesiones peritoneales correspondientes a carcinomatosis peritoneal. En el tacto rectal, una próstata fija y pétrea con recesos bilaterales comprometidos. El antígeno prostático específico estaba marcadamente elevado. La biopsia de las lesiones peritoneales confirmó adenocarcinoma prostático avanzado, T4N0M1, estadio IVb, Gleason X. Se realizó bloqueo androgénico completo y el paciente continúa en seguimiento a los 24 meses. La carcinomatosis peritoneal por carcinoma prostático es un diagnóstico diferencial que debe plantearse ante ascitis y patología tumoral prostática, siendo la sospecha clínica y los estudios citoquímicos el inicio del abordaje secuencial para un diagnóstico oportuno, estadificación tumoral y pronóstico.
Referências
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
World Heatlh Organization. Cancer Today [Internet]. [citado 2023 Jul 4]. Disponible en: https://gco.iarc.fr/today/fact-sheets- populations.
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63-89.
Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020;69(41):1473-1480.
Miranda O, García J, Vivanco B, Fernández JM, Sacristán R, Álvarez-Múgica M, et al . Metastasis subcutánea de cáncer de próstata. Arch Esp Urol. 2009;62(7):583-585.
Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, et al. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. Prostate. 2014;74(2):210-216.
Desai MM, Cacciamani GE, Gill K, Zhang J, Liu L, Abreu A, et al. Trends in Incidence of Metastatic Prostate Cancer in the US. JAMA Netw Open. 2022;5(3):e222246.
Tareen SA, Rodriguez J, Wu P. Prostate Cancer Metastatic to the Peritoneum: A Road Less Traveled by a Common Malignancy. Cureus. 2019;11(3):e4222.
Anwar A, Kasi A. Peritoneal Cancer. 1th ed. Treasure Island (FL): StatPearls Publishing; 2024.
Szadkowska MA, Pałucki J, Cieszanowski A. Diagnosis and treatment of peritoneal carcinomatosis – a comprehensive overview. Pol J Radiol. 2023;88:89-97.
García M, Vallejo M, Calderón P, Velasquez J, Feliciano J, Gutiérrez M, et al. Instituto Nacional de Cancerología. Protocolo clínico basado en la evidencia. Uso de la quimioterapia hipertérmica intraperitoneal (HIPEC) en pacientes con carcinomatosis peritoneal. Bogotá, Colombia. Instituto Nacional de Cancerología; 2016.
Jang HR, Lee K, Lim KH. Isolated peritoneal metastasis of prostate cancer presenting with Massive Ascites: A case report. Curr Oncol. 2022;29(7):4423–4427.
Achard V, Achard G, Friedlaender A, Roth A, Tille Jean-Christophe, Miralbell R, et al. Prostate cancer nonascitic peritoneal carcinomatosis after robot-assisted laparoscopic radical prostatectomy: case reports and review of the literature. Urology. 2020; 137:121–125.
Petrakis D, Pentheroudakis G, Kamina S, Pappa L, Papadiotis E, Malamou-Mitsi V, et al. An unusual presentation of a patient with advanced prostate cancer, massive ascites and peritoneal metastasis: Case report and literature review. J Adv Res. 2015;6(3):517–521.
Catton PA, Hartwick RW, Srigley JR. Prostate cancer presenting with malignant ascites: Signet- ring cell variant of prostatic adenocarcinoma. Urology. 1992;39(5):495–497.
Ji X, Wang L, Lin J, Tang K. Detection of diffuse peritoneal and omental metastases from prostate cancer with 18F-PSMA-1007 PET/CT. Clin Nucl Med. 2022;47(1):74-76.
Kwok AM. Locally advanced prostate cancer with peritoneal carcinomatosis causing large bowel obstruction. ANZ J Surg. 2020;90(9):1814–1816.
Appalaneni V, Yellinedi S, Baumann MA. Diagnosis of malignant ascites in prostate cancer by measurement of prostate specific antigen. Am J Med Sci. 2004;327(5):262–263.
Benedict SP, Ahuja M, Mammen KJ. Hormone refractory carcinoma prostate with peritoneal metastases and malignant ascites without skeletal involvement: A case report and review of literature. Indian J Urol. 2010;26(2):287-288.
Brehmer B, Makris A, Wellmann A, Jakse G. Solitäre Peritonealkarzinose eines Prostatakarzinoms. Aktuelle Urol. 2007;38(5):408-409.
Grabstald H, Chabon A, McSherry C. Prostate cancer: unusual metastases 20 years after 125iodine brachytherapy. J Urol. 1995;154(1):203- 204.
Gungor S, Asa S, Kupik O. FDG PET/CT in Peritoneal Metastasis From Prostate Cancer. Clin Nucl Med. 2016;41(9):e424-425.
Jang HR, Lee K, Lim KH. Isolated Peritoneal Metastasis of Prostate Cancer Presenting with Massive Ascites: A Case Report. Curr Oncol. 2022;29(7):4423-4427.
Kehinde EO, Abdeen SM, Al-Hunayan A, Ali Y. Prostate cancer metastatic to the omentum. Scand J Urol Nephrol. 2002;36(3):225-227.
Labanaris AP, Zugor V, Pokupic S, Afram S, Witt JH. Peritoneal dissemination of prostate cancer with the absence of lymph node, skeletal, or visceral metastases in a patient scheduled to undergo robot-assisted radical prostatectomy. J Robot Surg. 2013;7(2):201-204.
Ladwa R, Gustafson S, McCaffrey E, Miles K, O’Byrne K. A Rare Case of Omentum Invasive Prostate Cancer: Staging With PSMA PET/CT Imaging and Response to Systemic Therapy. Clin Nucl Med. 2017;42(6):e311-e312.
Lau KS, Le K, Bui C, Wong VCK, Mansberg R. Peritoneal Carcinomatosis From Metastatic Prostate Cancer Identified on 68 Ga-Prostate- Specific Membrane Antigen PET/CT. Clin Nucl Med. 2023 Aug 1;48(8):704-706.
Madaan S, Palit V, Gudgeon P, Biyani CS. Omental metastasis with malignant ascites: an unusual manifestation of prostatic adenocarcinoma. Can Urol Assoc J. 2007;1(3):288-290.
Rizk R, Danse E, Aydin S, Tombal B, Machiels JP. Castrate-resistant prostate cancer with peritoneal metastases treated with docetaxe-based chemotherapy. Urol Int. 2014;93(1):49-54.
Saif MW, Figg WD, Hewitt S, Brosky K, Reed E, Dahut W. Malignant ascites as only manifestation of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 1999;2(5/6):290-293.
Saini R, Dodagoudar C, Talwar V, Singh S. Malignant ascites with omental metastasis: a rare event in prostate cancer. JCMT. 2015;1:34-35.
Van Roekel C, Jonges TGN, Lock TMTW. What are the odds? Prostate metastases to ureter and peritoneum. BMJ Case Rep. 2018:225730.
Wynn SS, Nagabundi S, Koo J, Chin NW. Recurrent prostate carcinoma presenting as omental large cell carcinoma with neuroendocrine differentiation and resulting in bowel obstruction. Arch Pathol Lab Med. 2000;124(7):1074-1076.
Zagouri F, Papaefthimiou M, Chalazonitis AN, Antoniou N, Dimopoulos MA, Bamias A. Prostate cancer with metastasis to the omentum and massive ascites: a rare manifestation of a common disease. Onkologie. 2009;32(12):758-761.
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(9).
Koff A, Azar MM. Diagnosing peritoneal tuberculosis. BMJ Case Rep. 2020;13(2):e233131.
Arango M, Castañeda E, Agudelo CI, De Bedout C, Agudelo CA, Tobón A, et al. Histoplasmosis en colombia: Resultados de la Encuesta Nacional, 1992-2008. Biomédica. 2011;31(3):344-356.
Cáceres DH, Gómez BL, Restrepo A, Tobón A. Histoplasmosis y sida: factores de riesgo clínicos y de laboratorio asociados al pronóstico de la enfermedad. Infectio. 2012;16(3):44-50.
Allen VA, Takashima Y, Nayak S, Manahan KJ, Geisler JP. Assessment of False-negative Ascites Cytology in Epithelial Ovarian Carcinoma: A Study of 313 Patients. Am J Clin Oncol. 2017;40(2):175- 177.
Histopat [Internet]. Barcelona: cerba. NKX3.1; 2019 May [2020 Jun 3]. Disponible en: https:// www.histopat.es/2019/04/nkx3-1/
Liu H, Lin F, Zhai Q. Prostate Gland. En: Lin F, Prichard JW, Liu H, Wilkerson ML, editor. Handbook of Practical Immunohistochemistry. 3 ed. Danville: Springer, Cham; 2022. p. 523-550.
Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(9): 1119-1134.
Delchambre E, Rysselinck S, Pairet G, Confente C, Seront E. Isolated peritoneal carcinomatosis in prostate cancer: from a successful hormonal management to a review of the literature. Future Sci OA. 2021;7(6).
Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules. 2022;27(17):5730.
Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). J Urol. 2023;209(6):1082-1090.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Revista Médicas UIS